Skip to content
Screener

Mirum Pharmaceuticals, Inc. MIRM Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Gilead Sciences logo
Gilead SciencesGILD
$9M-66.7%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
$0-100%
LQD
Liquidia CorporationLQDA
$1.75M+38.6%
ALN
Alnylam PharmaceuticalsALNY
$33.56M-58.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$22.59M
Arrowhead Research logo
Arrowhead ResearchARWR
$46.83M

Other financials

Income statement

See full
Revenue$176.2M+37.9%
Operating income-$42.5M-753%
Net income-$67.2M-1,047%
EPS (diluted)-$1.06-783%

Balance sheet

See full
Cash & equivalents$262.7M+39.4%
Total debt$12.9M+29.2%
Total equity-$10.4M-104%
Total assets$1.0B+44.0%

Cash flow

See full
Operating cash flow-$44.3M-468%
CapEx$23.0K-81.7%
Free cash flow-$44.3M-472%

Valuation

See full
Market cap$6.45B+144%
Enterprise value$6.2B+151%
P/S10.4×+4.3×

Profitability

See full
Operating margin-134.9%-151pp
Net margin-139.2%-156pp
FCF margin-37%

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.9×-0.3×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The source filing: Mirum Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001759425-26-000045
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from issuance of convertible notes, net of issuance costs of $17,565672,435
Exchange and repurchase of 2029 convertible notes(474,365)
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs of $8,600259,948
Proceeds from issuance of common stock pursuant to equity plans23,49915,047
Net cash provided by financing activities481,51715,047
Effect of exchange rate on cash, cash equivalents and restricted cash(2,645)3,281
Net increase in cash, cash equivalents and restricted cash34,2975,674
Cash, cash equivalents and restricted cash at beginning of period298,165222,928

Item 1. Financial Statements (Unaudited)

FAQ

What is Mirum Pharmaceuticals, Inc.'s stock issuance proceeds?
Mirum Pharmaceuticals, Inc. (MIRM) reported stock issuance proceeds of $13.37M in Q2 2026.
How has Mirum Pharmaceuticals, Inc.'s stock issuance proceeds changed year-over-year?
Mirum Pharmaceuticals, Inc.'s stock issuance proceeds increased by 53.9% year-over-year, from $8.69M to $13.37M.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Ask your AI about Mirum Pharmaceuticals, Inc.'s stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude